title: [The future of transcatheter antitumor therapy].
abstract: Transcatheter antitumor therapy very quickly accepted during the last decade and their importance in the treatment of oncology patients will be increasing. By improvement of new targeted agents, which can be given intraarterial or systemic, efficiency of transcatheteric therapeutic approaches can be drastically increased. Numerous clinical trials (study phase I / II / III) relating to the synergy of two antitumor therapeutic approaches are already in progress. Preliminary results of these trials are already very encouraging. Further improvement in the development of specific therapeutics antitumor drugs and systemic applications will be a big step in the quest for medication against malignant tumors.
authors.affiliation: Medicinski fakultet u Beogradu Centar za Radiologiju i Magnetnu rezonancu, KC Srbije, Beograd.
authors.forename: D
authors.initials: D
authors.lastname: Masulović
authors.forename: M
authors.initials: M
authors.lastname: Milićević
authors.forename: R
authors.initials: R
authors.lastname: Stević
authors.forename: D
authors.initials: D
authors.lastname: Sagić
authors.forename: Dj
authors.initials: Dj
authors.lastname: Saranović
authors.forename: Lj
authors.initials: Lj
authors.lastname: Lazić
authors.forename: R
authors.initials: R
authors.lastname: Maksimović
authors.forename: K
authors.initials: K
authors.lastname: Randić
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D016461:Chemoembolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors